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Abstract
Background: The amount of surfactant deposited in the lungs and its overall pulmonary distribution determine the
therapeutic outcome of surfactant replacement therapy. Most of the currently available methods to determine the
intrapulmonary distribution of surfactant are time-consuming and require surfactant labelling. Our aim was to assess
the potential of Mass Spectrometry Imaging (MSI) as a label-free technique to qualitatively and quantitatively evaluate
the distribution of surfactant to the premature lamb.
Methods: Twelve preterm lambs (gestational age 126-127d, term ~150d) were allocated in two experimental groups.
Seven lambs were treated with an intratracheal bolus of the synthetic surfactant CHF5633 (200mg/kg) and 5 lambs
were managed with mechanical ventilation for 120min, as controls. The right lung lobes of all lambs were gradually
frozen while inflated to 20 cmH2O pressure for lung cryo-sections for MSI analysis. The intensity signals of SP-C analog
and SP-B analog, the two synthetic peptides contained in the CHF5633 surfactant, were used to locate, map and
quantify the intrapulmonary exogenous surfactant.
Results: Surfactant treatment was associated with a significant improvement of the mean arterial oxygenation and
lung compliance (p < 0.05). Nevertheless, the physiological response to surfactant treatment was not uniform across all
animals. SP-C analog and SP-B analog were successfully imaged and quantified by means of MSI in the
peripheral lungs of all surfactant-treated animals. The intensity of the signal was remarkably low in untreated
lambs, corresponding to background noise. The signal intensity of SP-B analog in each surfactant-treated
animal, which represents the surfactant distributed to the peripheral right lung, correlated well with the
physiologic response as assessed by the area under the curves of the individual arterial partial oxygen
pressure and dynamic lung compliance curves of the lambs.
Conclusions: Applying MSI, we were able to detect, locate and quantify the amount of exogenous surfactant
distributed to the lower right lung of surfactant-treated lambs. The distribution pattern of SP-B analog correlated well
with the pulmonary physiological outcomes of the animals. MSI is a valuable label-free technique which is able to
simultaneously evaluate qualitative and quantitative drug distribution in the lung.
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Introduction
Surfactant replacement therapy consists of delivering
exogenous surfactant directly to the lungs of babies suf-
fering from the Respiratory Distress Syndrome (RDS)
[1]. Although roughly 80% of the surfactant remains
within the lungs after approximately 30 min of intratra-
cheal administration [2, 3], its intrapulmonary distribu-
tion is often non-homogenous [4, 5], which has been
associated with poor clinical outcomes [6]. Pulmonary
surfactant distribution is governed by a number of
factors including the viscosity, surface tension and dens-
ity of the surfactant preparation [7], the administration
technique (e.g. instillation or aerosol delivery) [6, 8], the
administration volume and injection rate [4, 9], the type
of ventilation support (invasive/non-invasive), [2], the
position of the patients with respect to gravity and the
overall pulmonary status [10].
The investigation of the pulmonary distribution of ex-
ogenous surfactant has been the primary outcome of
several investigations comparing the efficacy of different
surfactant preparations [7, 10] or the feasibility of alter-
native surfactant administration techniques such as
nebulization [2, 6]. In most studies, the pulmonary
distribution of surfactant was determined with the tech-
nique of the radiolabeled microspheres [5, 6, 8, 9]. The
use of this technique is unfortunately limited by the
availability of appropriate facilities to handle radioactive
samples. Similar techniques based on non-radioactive
tracers were further developed and have also been
proven useful to assess the pulmonary distribution of
surfactant [11, 12]. Alternatively, imaging techniques
such as gamma scintigraphy or micro-PET-CT have
been employed to investigate the pulmonary distribution
of surfactant [2, 3]. All these techniques rely on the use
of a label which is added to the surfactant. Therefore,
one must assume that the label will equally distribute
with the surfactant within the lungs.
Mass-spectrometry imaging (MSI) provides comple-
mentary information to the traditional methods utilized
in drug distribution studies [13] and holds great poten-
tial as a tool to investigate the intrapulmonary distribu-
tion of exogenous surfactant. MSI is particularly
appealing because a wide array of both endogenous and
exogenous molecules can be localized based on their
mass-to-charge ratio (m/z) without the need of any sort
of labeling [14, 15]. In addition, the sensitivity of MSI
analysis is generally good enough to provide quantitative
data for the molecule of interest [16, 17].
The aim of this work was to assess the potential of
MSI analysis to simultaneously obtain qualitative and
quantitative data of the pulmonary distribution of
surfactant. To validate this proof of concept, we per-
formed a MSI analysis of lung sections of preterm lambs
treated with the synthetic surfactant CHF5633 (Chiesi
Farmaceutici, Parma, Italy), which contains the phospho-
lipids dipalmitoyl phosphatidylcholine (DPPC) and pal-
mitoyloleoyl phosphatidilglycerol (POPG) in a 1:1 ratio
and incorporates analogs of both hydrophobic surfactant
proteins (SP): SP-B and SP-C [18, 19]. SP-B and SP-C
analogs have 34 and 33 amino acid residues, respectively,
the former accounting for 0.2% of the whole surfactant
mass, and the latter for 1.5% of it. Our MSI strategy was
based on the intrapulmonary detection, mapping and
quantification of both synthetic peptides, by monitoring
their characteristic molecular ions following Matrix-
Assisted Laser Desorption Ionization (MALDI). Addition-
ally, we correlated the lung distribution data from the MSI
analysis with a set of physiological parameters characteriz-
ing the response of the individual animals.
Material and methods
Animal experiments
All animal experiments were performed after obtaining
approval from the animal welfare committee of the
University of Western Australia. Merino sheep were
time-mated to yield lambs of 126–127 days’ gestational
age (term 150 days). On the day of delivery, ewes were
sedated, intubated, and mechanically ventilated. Lambs
were surgically delivered. Following exposure of the fetal
head, an endotracheal tube was placed surgically and the
lamb was delivered. Animals were then weighed, dried, and
moved to an infant warmer bed (CosyCot, Fisher&Paykel,
Auckland, NZ). Mechanical ventilation was immediately
started using a Fabian ventilator (Acutronic Medical
Systems, Hirzel, Switzerland) and an umbilical arterial
catheter was placed. Sedation/analgesia was maintained
throughout the whole follow up period with intramuscular
ketamine (20mg upon initiation of ventilation, and as
needed).
All lambs were initially ventilated for 15 min with the
following ventilation settings: Positive Inspiratory Pres-
sure (PIP) limited to 35 cmH2O, Positive End-Expiratory
Pressure (PEEP) of 6 cmH2O, respiratory rate of 70/min,
and an inspiratory time of 0.3 s. A tidal volume (VT) of
5 mL/kg was targeted in this initial ventilation period.
The fraction of inspired oxygen (FiO2) was kept constant
at 100%. After the initial ventilation period, lambs were
allocated to one of the two experimental groups. The
first group of animals was treated with a 200 mg/kg dose
of CHF5633 by bolus airway instillation and further
supported with mechanical ventilation for 120min (SF-
Bolus group, n = 7). One-third of the dose was delivered
with the animal in the prone position, and 1/3 each in
left lateral and right positions with brief ventilation
between surfactant injections. A group of untreated
lambs managed with mechanical ventilation for a total
of 135 min (15 min of initial ventilation+ 120 min of fol-
low-up) served as Control group (n = 5). During the
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follow-up period, PIP was adjusted to maintain a VT of
6–7 mL/kg when possible. Arterial blood gases were
assessed after the initial period of mechanical ventilation
(before surfactant treatment), 5 min after surfactant
treatment and then at 30 min intervals for 120 min.
Heart rate (HR) and arterial blood pressure were con-
tinuously measured and recorded (SurgiVet monitors,
Smiths Medical). Airway flow, mean airway pressure
(MAP) and VT were monitored with a flow sensor
connected to the endotracheal tube. The flow sensor of
the Fabian ventilator (0.9 mL dead space) was calibrated
by occlusion prior to beginning of ventilation of the
lambs. The lambs were sedated with ketamine, thus did
not breath spontaneously and the dynamic compliance
(Cdyn) values could be reliably extracted from the venti-
lator. Cdyn was calculated by dividing the changes in
lung volume (ΔV, equivalent to VT, in mL) by the
changes in pressure (ΔP) standardized by the animal’s
weight:
Cdyn ¼ ΔV= ΔPWeightð Þ
At necropsy, lungs were removed, visually inspected
and separated into right and left lungs. The right lung
was inflated statically with air to 35 cmH2O and
suspended in a Dewar flask containing liquid nitrogen in
the bottom. Distending pressure was then decreased to
20 cmH2O and the lung froze above the liquid nitrogen
in the cold environment in about 15 min. The lungs
were delivered frozen on dry ice to the University of
Florence, where they were stored at − 80 °C until
analysis.
Sample preparation and MSI workflow
Additional information of the materials and the methods
describing the MSI analysis is available as supplementary
information (Additional file 1: Method S1). A single pre-
mature lamb lung has an approximate size of 12 × 8 cm
and its frontal section exceeds the standard size of the
histology glass used for MSI analysis. Therefore, samples
were transversally cut in four pieces of about the same
thickness (~ 3 cm) and the lower face of the third piece
was chosen for sectioning (Fig. 1a). This choice was
made in order to have a fair representation of surfactant
distribution in the peripheral parenchymal area.
Lung sections of 20 μm thickness were cut from
surfactant-treated (n = 7) as well as from untreated con-
trol animals (n = 5) using a cryomicrotome and were
thaw-mounted on conductive ITO glass and dried for
30 min in a standard desiccator.
The next steps consisted of spray-coating the lung
slides (Fig. 1b) with MALDI matrix using an appropriate
automated device. A 5 g/L solution of 4-chloro-α-cyano-
cinnamic acid in 50:50:0.2 H2O:ethanol: TFA solvent
mixture was employed to uniformly coat the glass slides.
A MALDI-TOF/TOF (Matrix-Assisted Laser Desorption
Ionization and tandem Time-Of-Flight) instrument
(Bruker UltraFlex III) was used for MSI data acquisition.
Setting the spatial resolution at 350 μm allowed analyz-
ing a full tissue section in approximately 8 h. The mass
spectrometer worked in positive ion reflectron mode
with full scan acquisition in the range 1200–4500m/z.
Fig. 1 Workflow of MSI analysis. The right lungs of lambs were cut
into four pieces of approximately 3 cm (a) and the lower face of the
third piece was cryo-sectioned and thaw-mounted onto a
conductive glass slide. Samples were then spray-coated with an
appropriate MALDI matrix (b). Samples were then analyzed with
MALDI-TOF/TOF instrumentation, acquiring spectra at defined spatial
intervals (c). Lastly, data were elaborated to create 2D ion intensity
maps of surfactant Protein B and C analogs and tissue slices were
stained with Hematoxylin and Eosin (d)
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Spectra were acquired by rastering the section surface
with a step of 350 μm in both x and y directions. 2D ion
intensity maps were then created by taking into consid-
eration the intensities of the ions resulting from the
ionization of of SP-C analog and SP-B analog (Fig. 1c-d).
Among the different characteristic ions, SP-C analog dis-
tribution was monitored by its [SP-C analog+Na]+
adduct ion (m/z 3618), while the [SP-B analog+H]+ ion
(m/z 3886) was selected for SP-B analog. All ion traces
were extracted with a tolerance of 1 Da. All statistical
analyses were performed on the log-transformed data in
order to compensate for the expected non-normal distri-
bution of MS data.
Calibration curve preparation for quantitative MSI
A six-point calibration curve of chemical standards of
SP-C analog and SP-B analog was performed by deposit-
ing drops of 0.5 μl of properly prepared solutions (50%
ethanol) containing the same amount of both peptides
over control homogenate lung tissue slices. Chemical
standards of the SP-C analog and SP-B analog were
synthesized and purified by Chiesi Farmaceutici labora-
tories (Parma, Italy). The absolute quantities of both
peptides in the 0.5 μl drops were as follows: point #1: 1
ng of both peptides, point #2: 2.5 ng, point #3: 5 ng,
point #4: 10 ng, point #5: 25 ng, point #6: 50 ng. To be
able to directly identify the deposition area of the stan-
dards on the MSI datasets, 6.25 ng of melittin standard
were added to the peptide mixture. A set of preliminary
tests was performed to optimize the melittin concentra-
tion. After spotting, the samples were sectioned, coated
with MALDI matrix and analyzed as described above.
Three sample replicates for each calibration curve were
prepared and included in calculations.
Software
The individual data files were exported in the open-
source imzML format by using the instrument control
software [20]. The individual ion images were extracted
from the imzML raw dataset by using a custom Python
library relying on the pyimzML parser. All data analyses
were performed in R (https://www.R-project.org/), rely-
ing on a set of packages to perform specific tasks. In
particular: Tidyverse and magrittr for data handling and
visualization, EBImage for image segmentation, Lme4 for
calibration curve estimation and raster, sp and rgeos for
spatial statistics.
Calibration curve optimization and estimation
Calibration curves for SP-C analog were estimated from
the measured signal for the [SP-C analog+Na]+ adduct
ion from the results of three independent experiments
(2 replicates) by applying a mixed effect modeling
approach. Prior to modeling, calibration spots were
preprocessed as follows: 1) In each experiment (and for
each ion) the pixels were classified into two groups and
the lower intensity population was used to identify the
background pixels. A clustering approach on the log-
transformed intensity was used to distinguish the two
populations. The “average” signal of the low-intensity
component was subtracted to compensate for the ex-
pected sample-to-sample analytical variability; 2) Mellitin
signal was used to identify the pixels which were actually
spotted with the standard mixture; 3) The average con-
centration per pixel in each dilution was calculated; and 4)
The best estimate for the calibration curve was obtained
by applying a mixed effects modeling approach:
SP−C analogpixel ¼ 3:1cpixel þ 0:2
where SP-C analogpixel represents the log10-transformed
signal of the [SP-C analog+Na]+ ion in each pixel and
cpixel is the actual spotted amount of SP-C analog in
nanograms. The calibration curves showed good repro-
ducibility. The 95% confidence intervals for the curve
parameters were also calculated from the fitting proced-
ure and were used to estimate the corresponding 95%
confidence intervals on the absolute concentrations.
MSI data normalization and preprocessing
The intensity measured in all pixels for all the sample is
shown in Fig. 2.
Each point in the plot displays the intensity of the two
ions at that specific position. The “violin” envelope
shows, instead, the density of the pixels along the inten-
sity axis. The plot for SP-C analog clearly allows distin-
guishing treated and untreated samples. In untreated
animals, however, the density profile shows a symmetric
and almost normal distribution, in line to what would be
expected in the presence of only background noise. In
the cases of treated samples, a higher intensity compo-
nent is superimposed to the “noise” distribution and is
composed of the pixels where a real signal correspond-
ing to one of the peptides was actually recorded. Consid-
ering their relative abundance in the surfactant, SP-C
analog shows a stronger signal compared to SP-B analog,
as expected. In addition, the variable position of the
maximum of the noise distribution indicates the pres-
ence of relevant differences in response across the differ-
ent samples. This type of sample-to-sample variability of
analytical origin is almost unavoidable in MSI and it is,
therefore, necessary to compensate in order to make the
results from different experiments comparable. In this
case, batch effect removal was performed by automatic-
ally subtracting to all intensities the mode of the density
distribution, which in practical terms means to set the
mean of the background intensity to zero. The effects of
such a form of batch correction are shown in Fig. 3.
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After batch correction, the density profile of untreated
samples was used to estimate a hard threshold (0.20) as
the 99.5 quantile of the overall intensity distribution.
This threshold was then used to identify the pixels be-
longing to the background. The same approach was
applied to the SP-B analog signal (threshold = 0.20).
In order to check the association of MSI data with the
physiological parameters, semi-quantitative results for
the two synthetic peptides in the different animals were
summarized in terms of the log10 average intensity of
the ion in the tissue section (Avg_log10_I) and the
absolute signal of the ion in the section from those
pixels with a signal above the noise level (Σ_log10_I).
Spatial statistics
To study the dependence of the SP-C analog signal on
the distance from the tissue border, the pixels belonging
to each tissue section were grouped in a series of non-
overlapping bins taking into account their distance from
the tissue border (in the range from 0.7 and 35.5 pixels).
Each bin signal was calculated as the median value of
the ionic signal recorded on the individual pixels.
Fig. 2 Violin plot showing the intensity distribution of SP-B analog and SP-C analog (measured as the SP-C analog-Na+ ion) in surfactant-treated
(Treated, SF) and in untreated control (Ctrl, C) animals
Fig. 3 Density plot showing the effects of the batch effect removal strategy on the SP-C analog-Na+ ionic signal for surfactant-treated (Treated,
SF) and in untreated control (Ctrl, C) animals. Empty lines show the normalized estimate of the probability distribution prior to batch correction.
Vertical black lines show the mode of the distribution showing the average intensity of the background pixels after correction. Vertical red lines
show the estimated threshold to identify background pixels
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Processing of physiological parameters
To compensate for an observed non-normality in the
distribution of arterial oxygen partial pressure (PaO2)
and PaCO2, these parameters were log10-transformed
prior to analysis. Animal-specific profiles were summa-
rized considering their area under the curve (AUC) and
the value at the final time point (120 min). PaO2, PaCO2,
pH, base excess (BE), Cdyn, PIP, VT, MAP, HR, arterial
systolic blood pressure (SBP), arterial diastolic blood
pressure (DBP), mean arterial blood pressure (MABP),
arterial oxygen saturation (SaO2), and temperature were
included in the analysis.
Statistical comparisons between the physiological
parameters of SF-Bolus and Control groups were
performed by Student’s t-test with Levene’s test for
equality of variances. The correlation between the
physiological parameters and the MSI data (Avg_log10_I
and Σ_log10_I) was investigated by correlation analysis.
Results
Physiological measurements
There were no significant differences between groups in
terms of gestational age (Control group: 126.5 ± 0.6; SF-
Inst group: 126.4 ± 0.5), body weight or fetal pH and
PaCO2 values (Table 1). According to fetal pH and
PaCO2 values, lambs were healthy before delivery.
Nevertheless, after 15 min of mechanical ventilation,
animals in both groups had severe acidosis, hypercarbia,
low arterial oxygenation, and low Cdyn values, indicating
lung immaturity.
Individual time-course curves of the physiological
parameters of each lamb included in the study are sum-
marized in Fig. 4. Generally, surfactant treatment was
associated with an increase of PaO2, pH, VT and Cdyn
and a decrease of PaCO2, PIP and MAP, as expected.
Nevertheless, the physiological response to surfactant
treatment was not uniform across all animals within the
SF-Bolus group. The effect of surfactant treatment on
the remaining physiological parameters was less appar-
ent (Additional file 1: Figure S1).
The AUC for each physiological parameter of each
animal as well as the values at 120 min were used to per-
form a t-test comparing surfactant-treated to untreated
control animals (Additional file 1: Table S1). From the
outcome of the statistical analysis, p values were used to
rank the most relevant physiological parameters
according to their difference between treated and un-
treated animals. Among the parameters, PaO2_AUC
showed the lowest p value (p = 0.0092), followed by the
parameters derived from Cdyn (Cdyn_AUC and Cdyn_120min,
p = 0.026 and p = 0.023, respectively) and by PIP_AUC
(p = 0.038).
MSI analysis
Reconstructed images based on the signals of SP-C and
SP-B analogs obtained from the lower right lung of each
lamb are shown in Figs. 5 and 6. Distribution maps show
the presence of both peptides in all samples of surfac-
tant-treated animals. In untreated animals, however, the
intensity of the signal is remarkably low and corresponds
to background noise. SP-C analog shows a fairly uniform
distribution across the lung sections of surfactant-treated
animals with some local accumulation of this peptide in
central areas (Fig. 5a).
The distribution maps of SP-B analog show a lower in-
tensity, mainly due to the lower abundance of this pep-
tide compared to SP-C analog in the CHF5633 drug
product but also to its relatively poor MALDI ionization
yield (Fig. 6a). As for the SP-C analog, spots of local ac-
cumulation of the SP-B analog are also evident in the
distribution maps. The investigation of the SP-C analog
signal as a function of distance from the tissue border
suggests reduced accessibility of peripheral lung regions
to the drug (Additional file 1: Figure S2).
The expected difference between surfactant-treated
and untreated control lungs is confirmed by the quanti-
tative data and by the set of intensity parameters sum-
marizing MSI results: Avg_log10_I and Σ_log10_I (Figs. 5
and 6b). The quantitative information on the concentra-
tion of SP-C analog is coherent among the different sec-
tions of surfactant-treated lungs, as demonstrated by the
superimposing confidence intervals (Fig. 5c).
Association of MSI data with the physiological parameters
The association between the physiological parameters
which were principally affected by surfactant treatment
(PaO2_AUC, Cdyn_AUC, and PIP_AUC) and the intensity pa-
rameters derived from the MSI analysis (Avg_log10_I and
Σ_log10_I) were assessed by calculating their Spearman cor-
relation (Fig. 7).
PaO2_AUC and Cdyn_AUC showed a strong, positive as-
sociation with the Avg_log10_I and Σ_log10_I of SP-B
Table 1 Fetal status and physiological measurements after 15 min of mechanical ventilation prior to surfactant treatment
Group BW (kg) Fetal (cord blood) Values after 15 min of mechanical ventilation
pH PaCO2 (mmHg) pH PaCO2 (mmHg) PaO2 (mmHg) PIP (cmH2O) Cdyn (ml/kg/cmH2O)
Control (n = 5) 2.7 ± 0.5 7.26 ± 0.02 68 ± 6 7.07 ± 0.07 110 ± 25 59 ± 22 34.2 ± 2.2 0.15 ± 0.05
SF-Inst (n = 7) 2.7 ± 0.4 7.22 ± 0.4 75 ± 9 7.01 ± 0.15 123 ± 40 52 ± 27 34.3 ± 1.3 0.12 ± 0.05
BW Birth weight, PaO2 Arterial oxygen partial pressure, PaCO2 Arterial carbon dioxide partial pressure, PIP Peak inspiratory pressure, Cdyn Dynamic compliance
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analog. PIP_AUC also showed a strong correlation with
SP-B analog but with the opposite trend. In the case of
SP-C analog, a slight association between PaO2_AUC, Cdy-
n_AUC, and PIP_AUC with Σ_log10_I persisted, while the
relation between the physiological parameters and Avg_
log10_I was not apparent.
Discussion
In this work, we applied MSI as a label-free technique to
investigate the pulmonary distribution of exogenous sur-
factant administered to preterm lambs with RDS. By
employing MSI, we were able not only to spatially
resolve the location of SP-C analog and SP-B analog
peptides in peripheral lung sections but also to quantify
the SP-C analog concentration at spatial intervals of
350 μm. Interestingly enough, the sum of the signal
intensity detected in the lower right lung for both pep-
tides, and in particular for SP-B analog, correlated well
with the pulmonary physiological parameters primarily
affected by surfactant treatment, suggesting a link
between the peripheral pulmonary distribution of
CHF5633 and the therapeutic outcomes of surfactant-
deficient lambs.
The aim of surfactant replacement therapy is to
achieve an even pulmonary distribution of the surfactant
in order to recruit as much collapsed alveolar areas as
possible. However, early surfactant distribution studies
already demonstrated a rather non-uniform pulmonary
distribution following surfactant instillation [4, 5]. An
even intrapulmonary surfactant distribution can be
achieved in preterm animals if the surfactant is instilled
at birth into the fluid-filled lung. Nevertheless, the distri-
bution is expected to be less uniform if the surfactant is
administered after a period of mechanical ventilation
[21]. Surfactant distribution studies have served to com-
pare the efficacy of different surfactant preparations, the
effects of different intratracheal injections rates [9], and
the outcomes after delivering surfactant by means of
alterative techniques such as nebulization [6, 8]. Most of
these distribution studies used radioactive microspheres
premixed with the surfactant to trace the intrapulmon-
ary fate of surfactant. Segerer et al. demonstrated that
the use of radioactive tracers could be replaced by
colored microspheres, which could be straightforwardly
detected by spectrophotometry [9]. Since then, different
non-radioactive labels have been used to address the
Fig. 4 Time course of the physiological parameters for each animal included in the study. Animals treated with surfactant are represented by red
lines (Treated) and untreated control animals are represented by blue lines (Ctrl). PaO2, arterial oxygen partial pressure; PaCO2, arterial carbon
dioxide partial pressure; PIP, peak inspiratory pressure; Cdyn, dynamic compliance; MAP, mean airway pressure; VT, tidal volume; HR, heart rate;
MABP, mean arterial blood pressure
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pulmonary distribution of surfactant [11, 12]. Nonethe-
less, these techniques are rather laborious and require
cutting the lungs in small pieces (70–200 pieces/lung
pair), which must be analyzed individually [8, 10, 12].
Gamma scintigraphy and micro-PET-CT have also been
used to assess surfactant distribution [2, 3]. Such
imaging techniques enable real-time investigation of
surfactant distribution, providing whole-lung qualitative
information about the surfactant distribution and allow-
ing for a semi-quantitative estimation of the amount of
intrapulmonary surfactant in each lung region [2]. How-
ever, the use of whole-body imaging techniques during
animal studies in the context of surfactant therapy is
often limited by the requirement of intensive care and
mechanical ventilation. This may, in turn, hamper the
transfer of animals to the imaging facility and eventually
the imaging process itself. Moreover, the aforementioned
techniques rely on the use of tracer molecules to detect
administered surfactant. Therefore, one must assume
that the tracer will remain associated with surfactant for
the duration of the experiment and that it will neither
interact nor be degraded upon contact with the
biological entities of the lungs. To address this issue,
Diemel et al. covalently-labelled SP-B with a fluorescent
tracer (BODIPY), which was incorporated into surfactant
and administered to LPS-exposed rats [22]. The fluores-
cent signal of SP-B could be then detected by micros-
copy in histological preparations. More recently,
Vukosavljevic et al. have applied linear Raman and
coherent anti-Stokes Raman scattering (CARS) micros-
copy as a label-free tool to detect the presence of intra-
cellular DPPC in primary human alveolar type II cells
[23]. This approach, however, has been applied at the
single-cell level so far.
In light of the limitations associated with the tech-
niques applied to investigate the intrapulmonary distri-
bution of surfactant, we envisaged MSI as a technique
that could overcome a number of the aforementioned
limitations, while offering significant advantages: 1) MSI
provides spatially-resolved images of surfactant distribu-
tion at good resolution [13]; 2) it allows for a quantita-
tive analysis of the analyte of interest [16, 17] (e.g. SP-C
analog and SP-B analog); 3) it is based on label-free
detection just requiring the ionization of the analyte of
interest [14, 15]; 4) sample processing can be mostly
automatized; and 5) MSI analysis does not require dedi-
cated in vivo experiments exclusively designed to assess
the pulmonary drug distribution, which enables
Fig. 5 a Reconstructed spatial distribution images of the SP-C analog in the lungs of surfactant-treated (SF) and untreated control (C) animals. b
Boxplots showing the difference of MSI-derived parameters (the log10 average intensity of ion inside the lung tissue section, Avg_log10_I; and
the absolute signal of the ion in the lung section from those pixels with a signal above the noise level, Σ_log10_I) in control (Ctrl) and surfactant-
treated animals. Quantification results for SP-C analog (c). Blue, horizontal lines in quantification charts identify the 95% confidence intervals
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Fig. 6 a Reconstructed spatial distribution images of the SP-B analog in the lungs of surfactant-treated (SF) and untreated control (C) animals. b
Boxplots showing the difference of MSI-derived parameters (the log10 average intensity of ion inside the lung tissue section, Avg_log10_I; and
the absolute signal of the ion in the lung section from those pixels with a signal above the noise level, Σ_log10_I) in control (Ctrl) and
surfactant-treated animals
Fig. 7 Association analysis between arterial oxygen partial pressure (PaO2), dynamic compliance (Cdyn) and peak inspiratory pressure (PIP) with
the log10 average intensity (Avg_log10_I) and the log10 sum of intensity values (Σ_log10_I) obtained for each lung section from the mass-
spectrometry imaging (MSI) analysis. PaO2, Cdyn and PIP values correspond to the area under the curve (AUC) for each surfactant-treated animal
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combining MSI experiments with the assessment of
other outcomes such as the physiological response to
surfactant treatment (e.g. PaO2 or Cdyn).
CHF5633 is a synthetic surfactant containing phos-
pholipids and two synthetic peptides mimicking key
sequences of SP-B and SP-C [18]. Native human SP-B
and SP-C have 79 and 35 amino acids [24, 25], whereas
SP-B analog and SP-C analog have 34 and 33 residues,
respectively [18]. Therefore, differences in number and
type of amino acids endow SP-B analog and SP-C analog
with distinct m/z ratios, which facilitated their detection
by means of MSI and allowed us to perform an accurate
study of the intrapulmonary localization of CHF5633
surfactant. The analysis provided qualitative and quanti-
tative data defining the pulmonary location as well as
the concentration of the analyzed peptides. The selectiv-
ity of the technique was further validated by the absence
of coherent intensity signals for SP-C analog and SP-B
analog in the lungs of animals that were merely managed
with mechanical ventilation and did not receive surfac-
tant. The total amount of SP-C analog and SP-B analog
in CHF5633 account for 1.5 and 0.2% of the surfactant
mass, respectively [19]. The higher amount of SP-C
analog in the formulation is in line with the observed
10-fold intensity difference registered after MSI analysis
favoring SP-C analog. Although the distribution of both
peptides throughout the lung slices of surfactant-treated
animals was ample, areas of local accumulation for both
peptides could be identified, suggesting a gradient-driven
distribution from the central lung towards the periphery.
SP-B and SP-C interact strongly with surfactant phos-
pholipids [26]; therefore, one would expect an equivalent
pulmonary distribution pattern for both analogs of the
CHF5633 formulation, since it is expected that they will
be transported along the airways bound to the phospho-
lipids. MSI analysis revealed markedly different intensity
profiles of both peptides across surfactant-treated ani-
mals, which indicates that the amount of surfactant
reaching the peripheral right lung as well as its distribu-
tion differed from animal to animal. This animal-to-ani-
mal variability in surfactant distribution towards the
lung periphery is intrinsic to bolus instillation in preterm
lambs [7, 27].
A further aim of this work was to investigate if the
physiological response elicited after CHF5633 adminis-
tration to premature lambs would correlate with the
surfactant distribution data from the MSI analysis. Previ-
ous studies have shown that the performance of
CHF5633 compares positively to that of commercially
available natural surfactant preparations [18, 19]. This
preparation has been shown to improve the pulmonary
function of premature animal models of severe RDS
without alterations of hemodynamics following instilla-
tion [18, 19, 28, 29] and is currently undergoing clinical
evaluation [30] (NCT02452476). In the present study,
surfactant administration produced a significant im-
provement of oxygenation and lung compliance, as ex-
pected. Nevertheless, the level of improvement differed
from animal to animal across surfactant-treated animals,
which we hypothesized would correlate with the MSI
study data.
In order to investigate the association between MSI
and physiological data, the AUC of PaO2, Cdyn and PIP
were deemed the most representative parameters of the
pulmonary outcome, whereas the Avg_log10_I and Σ_
log10_I were the selected parameters from the MSI ana-
lysis. Interestingly, the strongest correlations were found
between the MSI data of SP-B analog and the PaO2_AUC,
Cdyn_AUC and PIP_AUC. This finding is in line with previ-
ous studies highlighting the crucial role of SP-B for an
optimal surfactant function. Schürch et al. investigated
the independent effects of SP-B and SP-C in vitro by
supplementing organic lipid extracts with either one or
the other peptide [31]. In this study, SP-B outperformed
SP-C in terms of surface activity and stability perform-
ance, even though the simultaneous presence of both
peptides in the lipid extract obtained the best perform-
ance. In vivo, the essential role of SP-B is clearly demon-
strated by the death of SP-B knock-out mice shortly
after birth due to respiratory failure [32], which does not
occur in SP-C knock-out mice [33].
Despite the potential of MSI analysis in the preclin-
ical development of pulmonary drugs, we would like
to acknowledge some limitations of the technique
evaluation in the present study. Due to the relatively
large dimensions of the lungs of preterm lambs, we
decided to analyze representative lung sections of the
lower right lung, which we deemed appropriate to
validate the proof of concept of the study and signifi-
cantly reduced the MALDI-TOF/TOF scanning time.
We did not collect full histological data-sets to per-
form a sound histological study of the samples for
comparison with the MSI analyses. The localization of
native ovine SP-B and SP-C was not assessed in this
study due to the limited information available regard-
ing these proteins’ sequences and post-translational
modifications in the databases (e.g. UniProt). Never-
theless, there is a great interest inside the scientific
community towards MSI capabilities for drug distri-
bution studies as well as for the identification of
pathological conditions in human specimens for diag-
nostic purposes [34]. This evidence is nowadays en-
couraging the instrument developers to develop new
technical solutions in order to improve for example
laser repetition rate to speed the analyses, laser diam-
eter and focusing to increase the spatial resolution
and new designed MALDI ion source and plates to
allow the analysis of bigger tissue sections.
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Conclusion
This study provides a proof of concept for the applica-
tion of MSI as an advanced analytical tool to investigate
the intrapulmonary distribution of exogenous surfactant.
In this work, we were able to detect, locate and quantify
the amount of SP-B analog and SP-C analog in lung
sections of preterm lambs treated with the synthetic sur-
factant CHF5633, providing lung images and quantita-
tive data. Surfactant treatment significantly improved
the arterial oxygenation and the lung compliance of pre-
term lambs with RDS. Interestingly, such pulmonary
improvement correlated well with the distribution of the
SP-B analog towards the lower right lung. This study
postulates MSI as a valuable, label-free technique which
is able to simultaneously obtain qualitative and quantita-
tive data from preclinical drug distribution studies in the
context of pulmonary drug delivery.
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